David Miller CPA serves as Chief Financial Officer of the Company. He served as our Chief Financial Officer since May 2017 and was our Vice President, Finance from June 2013 till April 2017. Prior to joining the Company, Mr. Miller served as the Vice President of Finance and Operations at DMCWW, LLC, a private equity company focused on investing and operating start-up enterprises in the consumer technology space. From January 2006 to March 2010, Mr. Miller served as the Chief Financial Officer of NAF Funding, LLC, a nationwide financial services firm that brokers transactions involving the trading of life insurance policies. From January 2000 to December 2005, Mr. Miller was the Vice President of Finance and Operations at IDT Corp., where he led the creation and growth of the consumer phone services division to over one million customers of local and long distance service. From 1997 to 1999, he was an Assistant Vice President of the Internal Audit Department at Deutche Bank. Mr. Miller also held Senior Accountant positions at Schonbraun, Safris, Sternlieb, LLC and Margolin, Winer and Evans. Mr. Miller earned a B.S. from Yeshiva University in 1991 and an MBA from Fordham University in 1999. He is a Certified Public Accountant.
As the Chief Financial Officer of Champions Oncology Inc, the total compensation of David Miller at Champions Oncology Inc is 372,915$. There are 2 executives at Champions Oncology Inc getting paid more, with Ronnie Morris having the highest compensation of 1,343,650$.
David Miller is 51, he's been the Chief Financial Officer of Champions Oncology Inc since 2017. There are 8 older and 1 younger executives at Champions Oncology Inc. The oldest executive at Champions Oncology Inc is Abba Poliakoff, 68, who is the Independent Director.
David's mailing address filed with the SEC is C/O CHAMPIONS ONCOLOGY, INC., ONE UNIVERSITY PLACE, SUITE 307, HACKENSACK, NJ, 07601.
Over the last 21 years, insiders at Champions Oncology Inc have traded over 9,072,751$ worth of Champions Oncology Inc stock and bought 42,104,566 units worth 13,657,266$ . The most active insiders traders include Ventures Ix, L.P.Battery In...、Michael Maurice Brown、Sports Inc Champions. On average, Champions Oncology Inc executives and independent directors trade stock every 76 days with the average trade being worth of 2,196,294$. The most recent stock trade was executed by Daniel Newman Mendelson on 12 January 2024, trading 1,000 units of CSBR stock currently worth 6,500$.
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
Champions Oncology Inc executives and other stock owners filed with the SEC include: